EU AI Act Looms: Fines, Governance Gaps, and Salvaged R&D Define AI's Reality
Pedro's Take
This week's signals confirm what I have been telling clients for months: AI is no longer a theoretical discussion for European businesses. It is driving measurable outcomes, both positive and negative, and the regulatory clock for the EU AI Act is ticking louder. Firms must shift from casual adoption to strategic, governed implementation, understanding that both opportunity and serious risk are now inherent. Signal: Novo Nordisk salvaged a scrapped Parkinson's cell therapy project by partnering with an AI biotech. This demonstrates AI's ability to create value from previously failed R&D, offering a clear strategic advantage for European biotechs and CROs who can audit shelved projects for new pathways. Signal: A lawyer representing an accuser of Combs avoided jail time for an overdue AI fine. This confirms real consequences for lawyers failing to manage AI use, signaling precisely what European law firms will face with increasing frequency under the EU AI Act by August 2026. Signal: Alation introduced a new AI governance offering, indicating enterprise AI adoption currently outpaces governance efforts. This highlights the urgent need for European firms to define how AI is used, who accesses what data, and how decisions are made, establishing clear internal policies before mandatory compliance. The message is clear: AI is delivering real results and real risks, demanding immediate, disciplined action from European businesses.
The Week's Theme
This week, the AI Pulse shows its true colours: not just hype, but tangible results and concrete penalties. From rescuing stalled drug development to imposing fines for misuse, AI is demanding serious attention. European business owners must understand these shifts now, particularly with the EU AI Act approaching. The time for passive observation is over.